Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2022-06-22 Purchase | 2022-06-22 4:55 pm | Qualigen Therapeutics Inc. | QLGN | Poirier Michael S. Chairman and CEO | 30,000 | $0.57 | $17,100 | 210,207 (Indirect Direct) | View |
| 2022-06-14 Purchase | 2022-06-15 4:05 pm | Qualigen Therapeutics Inc. | QLGN | BROIDRICK AMY S. President/CSO | 30,000 | $0.62 | $18,600 | 34,500 (Direct) | View |
| 2021-08-19 Purchase | 2021-08-20 3:05 pm | Qualigen Therapeutics Inc. | QLGN | Kruger Kurt H Director | 8,000 | $1.225 | $9,800 | 18,000 (Direct) | View |
| 2021-04-26 Purchase | 2021-04-26 6:16 pm | Qualigen Therapeutics Inc. | QLGN | BROIDRICK AMY S. EVP, Chief Strategy Officer | 4,500 | $2.03 | $9,135 | 4,500 (Direct) | View |
| 2021-04-20 Purchase | 2021-04-21 3:18 pm | Qualigen Therapeutics Inc. | QLGN | Poirier Michael S. Chairman, CEO & President | 11,005 | $1.8 | $19,809 | 180,207 (Indirect Direct) | View |
| 2021-04-16 Purchase | 2021-04-19 06:15 am | Qualigen Therapeutics Inc. | QLGN | Lotz Christopher L. Vice President of Finance, CFO | 2,700 | $1.86 | $5,022 | 12,541 (Direct) | View |
| 2020-12-29 Purchase | 2020-12-30 06:05 am | Qualigen Therapeutics Inc. | QLGN | Kruger Kurt H Director | 4,000 | $2.935 | $11,740 | 10,000 (Direct) | View |
| 2020-11-20 Purchase | 2020-11-23 9:11 pm | Qualigen Therapeutics Inc. | QLGN | Kruger Kurt H Director | 6,000 | $3.4823 | $20,894 | 6,000 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2022-07-11 Option Award | 2022-08-04 4:17 pm | N/A 2032-07-11 | Qualigen Therapeutics Inc. | QLGN | Abdul-Ahad Wajdi Vice President, R & D, CSO | 80,000 | $0 | 80,000 (Direct) | View |
| 2022-07-11 Option Award | 2022-08-04 4:16 pm | N/A 2032-07-11 | Qualigen Therapeutics Inc. | QLGN | Lotz Christopher L. Vice President of Finance, CFO | 100,000 | $0 | 100,000 (Direct) | View |
| 2022-07-11 Option Award | 2022-08-04 4:16 pm | N/A 2032-07-11 | Qualigen Therapeutics Inc. | QLGN | ARSHAD TARIQ SVP/Chief Medical Officer | 102,000 | $0 | 102,000 (Direct) | View |
| 2022-07-11 Option Award | 2022-08-04 4:16 pm | N/A 2032-07-11 | Qualigen Therapeutics Inc. | QLGN | Ritter Ira E. Director | 40,000 | $0 | 40,000 (Direct) | View |
| 2022-07-11 Option Award | 2022-08-04 4:16 pm | N/A 2032-07-11 | Qualigen Therapeutics Inc. | QLGN | EMERY SIDNEY W JR Director | 40,000 | $0 | 40,000 (Direct) | View |
| 2022-07-11 Option Award | 2022-08-04 4:16 pm | N/A 2032-07-11 | Qualigen Therapeutics Inc. | QLGN | Kruger Kurt H Director | 40,000 | $0 | 40,000 (Direct) | View |
| 2022-07-11 Option Award | 2022-08-04 4:16 pm | N/A 2032-07-11 | Qualigen Therapeutics Inc. | QLGN | David Richard A. Director | 40,000 | $0 | 40,000 (Direct) | View |
| 2022-07-11 Option Award | 2022-08-04 4:16 pm | N/A 2032-07-11 | Qualigen Therapeutics Inc. | QLGN | Sinha Shishir K. VP, COO & Secretary | 100,000 | $0 | 100,000 (Direct) | View |
| 2022-07-11 Option Award | 2022-08-04 4:16 pm | N/A 2032-07-11 | Qualigen Therapeutics Inc. | QLGN | Poirier Michael S. Chairman and CEO | 375,000 | $0 | 375,000 (Direct) | View |
| 2022-07-11 Option Award | 2022-08-04 4:16 pm | N/A 2032-07-11 | Qualigen Therapeutics Inc. | QLGN | Korenberg Matthew E Director | 40,000 | $0 | 40,000 (Direct) | View |
| 2022-07-11 Option Award | 2022-08-04 4:16 pm | N/A 2032-07-11 | Qualigen Therapeutics Inc. | QLGN | BROIDRICK AMY S. President/CSO | 130,000 | $0 | 130,000 (Direct) | View |
| 2021-12-08 Option Award | 2021-12-10 06:15 am | N/A 2031-12-08 | Qualigen Therapeutics Inc. | QLGN | BROIDRICK AMY S. President/ChiefStrategyOfficer | 300,000 | $0 | 304,500 (Direct) | View |
| 2021-12-08 Option Award | 2021-12-10 06:15 am | N/A 2031-05-17 | Qualigen Therapeutics Inc. | QLGN | ARSHAD TARIQ SVP/Chief Medical Officer | 300,000 | $0 | 300,000 (Direct) | View |
| 2021-05-17 Option Award | 2021-05-18 06:14 am | N/A 2031-05-17 | Qualigen Therapeutics Inc. | QLGN | ARSHAD TARIQ SVP/Chief Medical Officer | 100,000 | $0 | 100,000 (Direct) | View |
| 2020-12-07 Option Award | 2020-12-29 4:44 pm | N/A 2030-12-07 | Qualigen Therapeutics Inc. | QLGN | BROIDRICK AMY S. Executive VP, CSO | 150,000 | $0 | 150,000 (Direct) | View |
| 2020-12-07 Option Award | 2020-12-08 12:31 pm | N/A 2030-12-07 | Qualigen Therapeutics Inc. | QLGN | EMERY SIDNEY W JR Director | 50,000 | $0 | 50,000 (Direct) | View |
Ownership | 2020-12-07 4:32 pm | N/A N/A | Qualigen Therapeutics Inc. | QLGN | EMERY SIDNEY W JR Director | 0 | $0 | 19,682 (Direct) | View |
| 2020-08-27 Option Award | 2020-08-28 2:01 pm | N/A 2030-08-27 | Qualigen Therapeutics Inc. | QLGN | BROIDRICK AMY S. Director | 50,000 | $0 | 50,000 (Direct) | View |
| 2020-06-06 Option Award | 2020-06-08 9:27 pm | N/A 2030-06-06 | Qualigen Therapeutics Inc. | QLGN | Ritter Ira E. Director | 50,000 | $0 | 50,000 (Direct) | View |
| 2020-06-06 Option Award | 2020-06-08 9:26 pm | N/A 2030-06-06 | Qualigen Therapeutics Inc. | QLGN | David Richard A. Director | 50,000 | $0 | 50,000 (Direct) | View |
| 2020-06-06 Option Award | 2020-06-08 9:26 pm | N/A 2030-06-06 | Qualigen Therapeutics Inc. | QLGN | Poirier Michael S. Chairman, President & CEO | 1,000,000 | $0 | 1,000,000 (Direct) | View |
| 2020-06-06 Option Award | 2020-06-08 9:24 pm | N/A 2030-06-06 | Qualigen Therapeutics Inc. | QLGN | Abdul-Ahad Wajdi Vice President, R & D, CSO | 500,000 | $0 | 500,000 (Direct) | View |
| 2020-06-06 Option Award | 2020-06-08 9:23 pm | N/A 2030-06-06 | Qualigen Therapeutics Inc. | QLGN | Kruger Kurt H Director | 50,000 | $0 | 50,000 (Direct) | View |
| 2020-06-06 Option Award | 2020-06-08 9:23 pm | N/A 2030-06-06 | Qualigen Therapeutics Inc. | QLGN | Sinha Shishir K. Vice President of Operations | 500,000 | $0 | 500,000 (Direct) | View |
| 2020-06-06 Option Award | 2020-06-08 9:22 pm | N/A 2030-06-06 | Qualigen Therapeutics Inc. | QLGN | Korenberg Matthew E Director | 50,000 | $0 | 50,000 (Direct) | View |
| 2020-06-06 Option Award | 2020-06-08 9:21 pm | N/A 2030-06-06 | Qualigen Therapeutics Inc. | QLGN | Lotz Christopher L. Vice President of Finance, CFO | 600,000 | $0 | 600,000 (Direct) | View |
Ownership | 2020-05-27 7:12 pm | N/A N/A | Qualigen Therapeutics Inc. | QLGN | SEKISUI DIAGNOSTICS LLC 10% Owner | 0 | $0 | 1,980,233 (Direct) | View |
| 2020-05-22 Other | 2020-05-27 6:07 pm | 2020-05-22 2024-01-31 | Qualigen Therapeutics Inc. | QLGN | Abdul-Ahad Wajdi VP, R&D, CSO | 16,828 | $0 | 16,828 (Direct) | View |
| 2020-05-22 Other | 2020-05-27 6:05 pm | 2020-05-22 2024-01-31 | Qualigen Therapeutics Inc. | QLGN | Sinha Shishir K. Vice President of Operations | 35,427 | $0 | 35,427 (Direct) | View |